Bob Ingram

10 results

Kelly Martin, former chief executive of Elan and co-founder of Malin. He left Malin in October last year, receiving a €3.2m exit settlement, compared to the €6.5m to which he was entitled.

Shareholders in Malin Corporation, the Dublin-based life sciences investment firm that’s reviewing its strategy in the wake of a share price slump and(...)

The Ireland Strategic Investment Fund is a 15 per cent shareholder in Malin, having invested €50 million in the group’s IPO.

Melinta Therapeutics, a company backed by Dublin-listed life sciences investment group Malin, is to gain a public listing on Nasdaq after agreeing a m(...)

Bob Ingram was last week appointed interim chairman of troubled the troubled firm. Photograph: Christinne Muschi/Reuters

Drug industry veteran Bob Ingram is developing a knack of landing tricky roles. Best known in Ireland for his chairmanship of Elan in its last days a(...)

The announcement marks Malin’s first new asset following its stock exchange debut earlier this year

Malin, an Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, has invested $35 million a(...)

Malin has said it will invest in companies for which an initial public offering (IPO) or trade sale is premature

Leading British fund manager Neil Woodford and the Irish state’s new strategic investment fund are among the investors who have committed to purchasin(...)

Malin has decided to target the funding needs of privately held early-stage life sciences business.

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)

Former Elan chief executive Kelly Martin (pictured) and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for $8.6 billion in 2013, will sit on the board of Malin

Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between €(...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

The idea started when Pablo Legorreta came across an innovative scheme pioneered by Paine Webber bankers.

It may be Dublin-based, but Royalty Pharma was unknown even here until it announced its interest in acquiring Elan, Ireland’s largest indigenous pharm(...)

Elan chief executive Kelly Martin: “There’s always a Plan B and a C.” Photograph: Alan Betson

Irish drug-maker Elan will lay out an alternative strategy if shareholders reject a string of planned deals and thereby make a bid from a US-based inv(...)